Skip to main content
In stock | Immunotherapy (Checkpoint Inhibitor)

Zalifrelimab

Oncology Type Solid Tumour
Drug Class / Mechanism Anti-CTLA-4 mAb
No Image
Description

Zalifrelimab is classified as an Anti-CTLA-4 mAb, sourced for use within our Immunotherapy (Checkpoint Inhibitor) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Immunotherapy (Checkpoint Inhibitor)
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3